US EditionNovo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer
Novo Nordisk raised its bid to $10 billion for Metsera, offering a 159% premium over pre-bid prices to acquire the promising weight-management drug MET-097i.
- On Tuesday, Novo Nordisk launched an unsolicited bid valuing Metsera Inc. at up to $86.20 per share, totaling about $10 billion, Metsera said.
- Seeking a stronger weight-management pipeline, Novo Nordisk aims to acquire Metsera to add MET-097i, a mid-stage candidate with promising once-monthly dosing and good tolerability.
- Amid the bids, Pfizer has filed lawsuits and revised its offer, countering Novo Nordisk's $62.20 per share plus $24 contingent value right with a $70 per-share proposal valuing Metsera at roughly $8.1 billion.
- Metsera said Novo Nordisk's bid is `superior` and could terminate its Pfizer merger if its board prefers Novo after negotiations.
- Amid a shifting weight-loss market, the bidding war reflects shifts as Novo Nordisk vies with Pfizer, which alleged anticompetitive conduct and filed lawsuits over MET-097i.
20 Articles
20 Articles
The struggle between the pharmaceutical giants Pfizer and Novo Nordisk for the purchase of Metsera, a drug developer against obesity, intensified Tuesdays when both companies presented improved offers, Metsera said that the offer of 10...
Danish pharmaceutical company Novo Nordisk has raised its bid for American biotech company Metsera, bringing the total acquisition package to a value of ten billion dollars. Metsera announced in a company statement...
Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates
Metsera said Tuesday that Pfizer and Novo Nordisk both upped their bids to acquire the obesity startup, with Novo’s offer coming in higher, valuing the company for up to $10 billion. Under Novo’s new proposal, it would pay $62.20 per share in exchange for half of Metsera’s shares upon signing the deal (up from its earlier offer of $56.50), which Metsera would pay out to shareholders as a dividend. After the deal is approved by shareholders and r…
Coverage Details
Bias Distribution
- 42% of the sources lean Left, 42% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
